C
enturies ago, fever was considered a single condition or disease and it was treated by a single form of intervention, blood-letting. 1 Later, we learned that fever has multiple causes that require very different interventions. Today, we treat hypertension in a similar way. Treatment guidelines and clinical practice make no real distinction between the different pathophysiological types of hypertension. The mantra-choose any of the large number of antihypertensive agents representing 10 different drug classes with different mechanisms of action and if the first choice does not work, add a second, a third, or a fourth drug type. This approach leads to an overutilization of drugs per patient and has been associated with poor outcomes. The excessive costs, medical and financial, are borne by patients and society.
Sealey and Laragh 2 have over many years provided an understanding of how hypertension really has multiple pathophysiologies that responds selectively or fails to respond to different drug treatment modalities. Thus, the time has come to examine ways to make treatment of hypertension more rationale and, thereby, more cost-efficient. There is growing evidence that better blood pressure control can be achieved without increasing the number of agents. 3 In fact, one would ultimately expect a lower number of drugs per patient. The solution lies in the selection of the right initial drug for each patient. An added bonus to society with this approach is that it could in all cases be accomplished using less expensive generic agents.
There are several objectives: First, decisions regarding treatment of a hypertensive person should be individualized. The "any size fits all" approach should have no place in hypertension treatment today.
Second, more sensible algorithms for individual treatment approaches should be developed and tested. From a public health viewpoint, this is more important than developing new antihypertensive agents.
Third, the overall goal should be to achieve much better blood pressure control in the population. This is likely to be accomplished by more rationale use of the currently available classes of drugs.
Types of hypertension
Pathophysiologically, there appears to be four major types of hypertension that require different initial drug treatment: This proposed categorization of hypertension based on seminal work by Laragh and Sealey could in the future form the foundation for individualized treatment of hypertensive persons, if documented to work in the clinical setting.
Treatment implications
The documentation in support of the proposed treatment algorithm is limited at this time. Recent data from ALLHAT 5 are encouraging. Approximately 28% of participants randomized to chlorthalidone were controlled on monotherapy after 60 months. One would assume that they represent low-renin hypertension.
Similarly, approximately 24% of those randomized to lisinopril were controlled on monotherapy after 60 months. 
EDITORIAL
The assumption is that they represent medium-/high-renin hypertension responding to antirenin system drugs. Thus, if these two groups are mutually exclusive, more than half of all hypertensive persons would be controlled on monotherapy. A proof-of-concept study 3 of 39 patients with uncontrolled hypertension despite taking an average of three drugs showed very encouraging results. The renin-guided treatment normalized the uncontrolled blood pressures (reduction of mean systolic blood pressure of 29 mm Hg) without any increases in number of antihypertensive drugs per patient. The conclusion is that individualized renin-guided treatment has great promise.
More research including randomized clinical trials are needed to determine the clinical implications of the proposed algorithm. The renin-guided treatment approach ought to be compared to a "JNC-7 approach" with mortality/ morbidity outcomes. The clinical alternative-to continue treating hypertension the way we treated fever centuries ago-cannot be justified and is the reason for the failing report card.
